Key result
High-dose cytarabine and mitoxantrone combined with venetoclax (HAM-VEN) is a highly active salvage regimen for relapsed or refractory acute myeloid leukemia, achieving a 69% composite complete remission rate in a real-world analysis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tettero et al. (2026) conducted an editorial in Relapsed or refractory acute myeloid leukemia (R/R AML). HAM-VEN (high-dose cytarabine, mitoxantrone, and venetoclax) was evaluated. High-dose cytarabine and mitoxantrone combined with venetoclax (HAM-VEN) is a highly active salvage regimen for relapsed or refractory acute myeloid leukemia, achieving a 69% composite complete remission rate in a real-world analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: